# Abuse-Deterrant Opioid Formulations & Comparators

_____

[Detailed study overview](https://www.opioiddata.org/studies/counfounding-opioid-safety-studies/) at the full project site [OpioidData.org](https://www.opioiddata.org)
<br>

_____

##### **Full list of NDCs for abuse-deterrent formulations of opioids for analytic purposes can be found [here](ADF_NDCs.csv)**

_____

This document contains information on (1) abuse-deterrent formulations (ADF) of opioids, (2) active comparator choices for research on ADFs, and (3) inactive comparator choices for research on ADFs.
_____

### Abuse-Deterrent Formulations

|Drug Name|NDA#|Categories of Evidence|Intended Route of Deterrence|Documentation|Status|ER/IR|
|---|---|-----------|---------|--------|---|---|
|OxyContin|22-272|**Injection:** Category 1<br>**Intranasal:** Category 1, Category 3|Intravenous, intranasal|[Drugs@FDA: OxyContin](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022272)<br><br>[OxyContin NDCs](OxyContin/oxycontin_NDCs.csv)<br><br>[OxyContin Documentation](OxyContin)|Active|ER|
|Hysingla ER|206627|**Intranasal & oral:** Category 1, Category 3<br>**Injection:** Category 1|Intravenous, intranasal, oral|[Drugs@FDA: Hysingla ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206627)<br><br>[Hysingla NDCs](Hysingla_ER/hysingla_NDCs.csv)<br><br>[Hysingla Documentation](Hysingla_ER)|Active|ER|
|MorphaBond ER|206544|**Injection:** Category 1<br>**Intranasal:** Category 1, Category 3|Intravenous, intranasal|[Drugs@FDA: MorphaBond ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206544)<br><br>[MorphaBond NDCs](MorphaBond_ER/morphabond_NDCs.csv)<br><br>[MorphaBond Documentation](MorphaBond_ER)|Discontinued|ER|
|Xtampza ER|208090|**Intranasal & oral:** Category 1, Category 2, Category 3<br>**Injection: Category 1**|	Intravenous, intranasal, oral|[Drugs@FDA: Xtampza ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208090)<br><br>[Xtampza NDCs](Xtampza_ER/xtampza_NDCs.csv)<br><br>[Xtampza Documentation](Xtampza)|Active|ER|
|RoxyBond|209777|**Injection:** Category 1<br>**Intranasal:** Category 1, Category 3|Intravenous, intranasal|[Drugs@FDA: RoxyBond](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209777)<br><br>[RoxyBond Documentation](RoxyBond)|Discontinued|IR|
|Embeda|022321|**Oral & Intranasal:** Category 1, Category 2, Category 3|Oral, intranasal|[Drugs@FDA: Embeda](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process)<br><br>[Embeda NDCs](Embeda/embeda_NDCs.csv)<br><br>[Embeda Documentation](Embeda)|Discontinued|ER|
|Arymo ER|208603|**Injection:** Category 1<br>**Intranasal:** Category 1, Category 3|Intravenous, intranasal|[Drugs@FDA: Arymo ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process)<br><br>[Arymo NDCs](Arymo_ER/arymo_NDCs.csv)<br><br>[Arymo Documentation](Arymo)|Discontinued|ER|
|Targiniq|205777|Category 1, Category 3|Intravenous, intranasal|[Drugs@FDA: Targiniq](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process)<br><br>[Targiniq Documentation](Targiniq)|Discontinued|ER|
|Troxyca ER|207621|Category 1, Category 2, Category 3|Oral, intranasal|[Drugs@FDA: Troxyca ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process)<br><br>[Troxyca Documentation](Troxyca)|Discontinued|ER|
|Oxaydo/Oxecta|202080|Category 3|Intranasal|[Drugs@FDA: Oxaydo](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process)<br><br>[Oxaydo/Oxecta NDCs](Oxaydo/oxaydo_NDCs.csv)<br><br>[Oxaydo Documentation](Oxaydo)|Active|IR|

_____

### Active Comparators

|Class|Ingredient|ER/LA or IR|Form|Documentation|Comments|
|---|---|---|-----|-----------|-----------|
|Opioid|Morphine|ER|Tablet, Capsule|NDC|Primary comparator|
|Opioid|FentanylER||Transdermal Patch|NDC|Primary comparator|
|Opioid|Methadone|?LA|Tablet, Capsule|NDC|Primary comparator|
|Opioid|Oxymorphone|ER|Tablet||Secondary comparator - OxyContin: Reformulated in XXXX, low market share|
|Opioid|Oxycodone|IR|Tablet||Secondary comparator - OxyContin: IR instead of ER, often used to treat acute pain|
|Opioid|Hydromorphone|IR|Tablet||Secondary comparator - OxyContin: IR instead of ER, often used to treat acute pain|
_____

### Inactive Comparators

|Class|Drug Name|Documentation|Comments|
|---|---|-----------|---------|
|Benzodiazepine||||
|SSRI||||
|Gabapentin||||
